SPECTRAL STUDIES OF THE INTERACTION BETWEEN SOLIFENACIN SUCCINATE AND HERRING SPERM DNA
Keywords:
Solifenacin succinate, Herring sperm DNA, Spectral studies, InteractionAbstract
Objective: The interaction between solifenacin succinate (SFS) and herring sperm DNA (Hs-DNA) was investigated by using UV–vis and fluorescence spectra at pH 7.4.
Methods: The UV-vis and fluorimetric titrations were performed by keeping the concentration of SFS constant and varying the concentration of Hs-DNA in a buffer solution of pH 7.4. The absorption spectra shows an increase in absorbance at an absorption band of SFS with increasing concentration of Hs-DNA. A quenching of intrinsic fluorescence of SFS was observed with the increasing of Hs-DNA concentration.
Results: The fluorescence lifetime results, the varieties of the fluorophore absorption spectra and the decrease of the binding constant with the increasing temperature all indicate that the fluorescence quenching is static. The ratio and constant of the binding Hs-DNA to SFS are 1 and 6.76 x 105, respectively. The values of ΔH, ΔS and ΔG obtained for SFS-Hs-DNA were - 9.93 kJ/mol, 0.17 kJ/(mol K) and - 44.78 kJ/mol respectively at 298 K.
Conclusions: The absorption spectra and fluorescence quenching spectra of SFS in presence of Hs-DNA strongly supports the interaction of SFS with Hs-DNA. SFS binds to Hs-DNA with a binding constant of 6.76 x 105 at 298 K. In addition, thermodynamic data for the SFS binding to Hs-DNA showed that the binding of SFS to Hs-DNA is not only exothermic but entropy-driven.
Â
Downloads
References
Li SY, Ren YZ, Zhao FL. Chinese Chemical Letters 2006;17(8):1065-68.
Maiti M, Kumar GS. Molecular aspects on the interaction of protoberberine, benzophenanthridine, and aristolochia group of alkaloids with nucleic acid structures and biological perspectives. Medicinal Res Rev 2007;27(5):649-95.
Cardozo L, Lisec M, Millard R, et al. Randomized. Double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urology 2004;172(5 Pt 1):1919-24.
Garely AD, Kaufman JM, Sand PK. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: Clinical Therapeutic 2006;28:1935-46.
Yanagihara T, Aoki T, Soeishi Y, Iwatsubo T, Kamimura H. Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography, J Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2007;859 (2):241-5.
Mistri HN, Jangid AG, Pudage A, Rathod DM, Shrivastav PS. Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective α1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma. J Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2008;876(2):236-44.
Singh L, Nanda S. Spectrophotometric estimation of Solifenacin succinate in tablet formulations. Pharmaceutical Methods 2011;2(1):21-4.
Xu JG, Wang ZB. Fluorimetry, third edition. Science Press: Beijing; 2006.